INTRODUCTION: Deep venous thrombosis (DVT) resolution involves the plasmin and the matrix metalloproteinase (MMP) system. This study tested the hypothesis that pharmacological inhibition of the plasmin system would impair DVT resolution and worsen vein wall damage. METHODS: A rat model of stasis DVT by inferior vena cava (IVC) ligation was performed with intravenous control saline or aprotinin (AP; 2.8 mg/kg at operation), and harvest of thrombosed IVC at 7 days. After laser Doppler imaging, DVT were separated and weighed, and vein wall stiffness was assessed by tensiometry. Thrombus and vein wall tissue analysis included total collagen by colorimetric assay, cytokines, chemokines, and d-dimer by ELISA, urokinase-plasminogen activator (uPA), and plasminogen activator inhibitor-1 (PAI-1) by immuno-blotting, MMP-2 and -9 by zymography, and neutrophil (PMN) and monocyte (ED-1) leukocytes by immunohistochemistry. RESULTS: DVT weights were 2-fold greater in the AP-treated rats (P < 0.05), but no significant differences in thrombus perfusion, collagen, or d-dimer levels were found. Vein wall stiffness was reduced 50% (P < 0.05), suggesting less biomechanical injury. The total vein wall MMP-9 was increased (P < 0.05) 5-fold in the AP group compared with controls, while MMP-2 was elevated but did not reach significance. No difference was found in vein wall tumor necrosis factor-alpha, tissue growth factor-beta, vein wall or thrombus monocytes, PMN, or uPA/PAI-1 ratio between groups. DISCUSSION: AP inhibition of the plasmin system was associated with larger thrombi but less vein wall injury, but no difference in other measures of resolution, possibly because of increased vein wall MMP-9 activity. These data suggest an important redundant mechanism for DVT resolution.
INTRODUCTION:Deep venous thrombosis (DVT) resolution involves the plasmin and the matrix metalloproteinase (MMP) system. This study tested the hypothesis that pharmacological inhibition of the plasmin system would impair DVT resolution and worsen vein wall damage. METHODS: A rat model of stasis DVT by inferior vena cava (IVC) ligation was performed with intravenous control saline or aprotinin (AP; 2.8 mg/kg at operation), and harvest of thrombosed IVC at 7 days. After laser Doppler imaging, DVT were separated and weighed, and vein wall stiffness was assessed by tensiometry. Thrombus and vein wall tissue analysis included total collagen by colorimetric assay, cytokines, chemokines, and d-dimer by ELISA, urokinase-plasminogen activator (uPA), and plasminogen activator inhibitor-1 (PAI-1) by immuno-blotting, MMP-2 and -9 by zymography, and neutrophil (PMN) and monocyte (ED-1) leukocytes by immunohistochemistry. RESULTS: DVT weights were 2-fold greater in the AP-treated rats (P < 0.05), but no significant differences in thrombus perfusion, collagen, or d-dimer levels were found. Vein wall stiffness was reduced 50% (P < 0.05), suggesting less biomechanical injury. The total vein wall MMP-9 was increased (P < 0.05) 5-fold in the AP group compared with controls, while MMP-2 was elevated but did not reach significance. No difference was found in vein wall tumor necrosis factor-alpha, tissue growth factor-beta, vein wall or thrombus monocytes, PMN, or uPA/PAI-1 ratio between groups. DISCUSSION: AP inhibition of the plasmin system was associated with larger thrombi but less vein wall injury, but no difference in other measures of resolution, possibly because of increased vein wall MMP-9 activity. These data suggest an important redundant mechanism for DVT resolution.
Authors: Daniel D Myers; Peter K Henke; Patricia W Bedard; Shirley K Wrobleski; Neelu Kaila; Gray Shaw; Thomas R Meier; Angela E Hawley; Robert G Schaub; Thomas W Wakefield Journal: J Vasc Surg Date: 2006-09 Impact factor: 4.268
Authors: John E Rectenwald; K Barry Deatrick; Pasu Sukheepod; Erin M Lynch; Andrea J Moore; Daria M Moaveni; Nicholas A Dewyer; Nicholas A Deywer; Catherine E Luke; Gilbert R Upchurch; Thomas W Wakefield; Steven L Kunkel; Peter K Henke Journal: J Vasc Surg Date: 2006-04 Impact factor: 4.268
Authors: Manu R Varma; Daria M Moaveni; Nicholas A Dewyer; Andrea J Varga; K Barry Deatrick; Steven L Kunkel; Gilbert R Upchurch; Thomas W Wakefield; Peter K Henke Journal: J Vasc Surg Date: 2004-09 Impact factor: 4.268
Authors: Peter K Henke; Andrea Varga; Sumit De; C Barry Deatrick; Jonathon Eliason; Douglas A Arenberg; Pasu Sukheepod; Porama Thanaporn; Steven L Kunkel; Gilbert R Upchurch; Thomas W Wakefield Journal: Arterioscler Thromb Vasc Biol Date: 2004-04-22 Impact factor: 8.311
Authors: Peter K Henke; Manu R Varma; K Barry Deatrick; Nicholas A Dewyer; Nicholas A Drewyer; Erin M Lynch; Andrea J Moore; Derek A Dubay; Pasu Sukheepod; Charles G Pearce; Gilbert R Upchurch; Steven L Kunkel; Michael G Franz; Thomas W Wakefield Journal: Thromb Haemost Date: 2006-02 Impact factor: 5.249
Authors: Nicholas A Dewyer; Osama M El-Sayed; Catherine E Luke; Megan Elfline; Nicolai Kittan; Ron Allen; Adriana Laser; Carson Oostra; Anthony Comerota; Cory Hogaboam; Steven L Kunkel; Peter K Henke Journal: Thromb Haemost Date: 2015-07-16 Impact factor: 5.249
Authors: Vikram Sood; Cathy Luke; Erin Miller; Mayo Mitsuya; Gilbert R Upchurch; Thomas W Wakefield; Dan D Myers; Peter K Henke Journal: Ann Vasc Surg Date: 2010-02 Impact factor: 1.466
Authors: Kristopher B Deatrick; Megan Elfline; Nichole Baker; Catherine E Luke; Susan Blackburn; Catherine Stabler; Thomas W Wakefield; Peter K Henke Journal: J Vasc Surg Date: 2010-09-24 Impact factor: 4.268
Authors: Hassan Albadawi; Avery A Witting; Yash Pershad; Alex Wallace; Andrew R Fleck; Peter Hoang; Ali Khademhosseini; Rahmi Oklu Journal: Cardiovasc Diagn Ther Date: 2017-12
Authors: Kristopher B Deatrick; Catherine E Luke; Megan A Elfline; Vikram Sood; Joseph Baldwin; Gilbert R Upchurch; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke Journal: J Vasc Surg Date: 2013-03-13 Impact factor: 4.268
Authors: Christine Chabasse; Suzanne A Siefert; Mohammed Chaudry; Mark H Hoofnagle; Brajesh K Lal; Rajabrata Sarkar Journal: J Vasc Surg Venous Lymphat Disord Date: 2014-05-10